We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

98 hedge funds and large institutions have $93M invested in Palvella Therapeutics in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 28 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 28

0.02% less ownership

Funds ownership: 0.82% → 0.81% (-0.02%)

7% less funds holding

Funds holding: 105 → 98 (-7)

24% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 21

53% less capital invested

Capital invested by funds: $199M → $93M (-$106M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $84K

Holders
98
Holders Change
-7
Holders Change %
-6.67%
% of All Funds
2.18%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
16
Increased
36
Reduced
28
Closed
21
Calls
–
Puts
$84K
Net Calls
-$84K
Net Calls Change
+$279K

Top Buyers

1
BI
BVF Inc
California
+$7.2M
2
NCM
Nantahala Capital Management
Connecticut
+$2.8M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$2.42M
4
Renaissance Technologies
Renaissance Technologies
New York
+$2.33M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.32M

Top Sellers

1
O
OrbiMed
New York
-$13.8M
2
PM
Prosight Management
Texas
-$5.15M
3
Millennium Management
Millennium Management
New York
-$3.04M
4
ACM
Aquilo Capital Management
California
-$2.96M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$19.8M +$7.2M +23,217 +33%
BlackRock
2
BlackRock
New York
$7.15M -$4.34K -14 -0%
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$5.96M +$275K +885 +3%
TCM
4
Tekla Capital Management
Massachusetts
$5.55M – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$5.28M +$2.33M +7,504 +43%
NCM
6
Nantahala Capital Management
Connecticut
$3.61M +$2.8M +9,028 +114%
ACM
7
Aquilo Capital Management
California
$3.22M -$2.96M -9,554 -39%
Millennium Management
8
Millennium Management
New York
$2.45M -$3.04M -9,797 -46%
State Street
9
State Street
Massachusetts
$2.41M -$9.93K -32 -0.3%
OFM
10
Omega Fund Management
Massachusetts
$2.07M – – –
Assenagon Asset Management
11
Assenagon Asset Management
Luxembourg
$2.05M +$2.42M +7,816 +433%
SFM
12
Sphera Funds Management
Israel
$1.86M -$794K -2,559 -23%
American Century Companies
13
American Century Companies
Missouri
$1.73M +$689K +2,220 +38%
Goldman Sachs
14
Goldman Sachs
New York
$1.66M -$63K -203 -3%
Arrowstreet Capital
15
Arrowstreet Capital
Massachusetts
$1.61M -$1.01M -3,269 -30%
LOAMU
16
Lombard Odier Asset Management (USA)
New York
$1.36M +$416K +1,340 +26%
PIM
17
Platinum Investment Management
Australia
$1.32M +$1.17M +3,784 +158%
Northern Trust
18
Northern Trust
Illinois
$1.23M -$96.2K -310 -5%
Vanguard Group
19
Vanguard Group
Pennsylvania
$1.19M +$298K +960 +21%
WCM
20
Wedge Capital Management
North Carolina
$1.13M +$592K +1,907 +56%
OAM
21
Oxford Asset Management
United Kingdom
$1.12M +$1.07M +3,436 +187%
SIM
22
Spark Investment Management
New York
$958K +$863K +2,782 +162%
Point72 Asset Management
23
Point72 Asset Management
Connecticut
$909K +$1.32M +4,271 New
PM
24
Prosight Management
Texas
$885K -$5.15M -16,613 -80%
RPAM
25
Rhenman & Partners Asset Management
Sweden
$798K – – –
1
2 3 4 5

PVLA Hedge Fund Activity: Q4 2018 in Review

98 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2018, worth a combined $93M — down 53% from $199M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of PVLA and 16 opened new positions — a net loss of 5 holders — while 28 trimmed existing stakes and 36 added.

The largest buyer was BVF Inc, adding an estimated $7.2M. The largest seller was OrbiMed, exiting entirely with an estimated $13.8M sold.

  • 98 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2018, down from 105 in Q3 2018.
  • Funds reported $93M of Palvella Therapeutics stock for Q4 2018, down 53% quarter-over-quarter.
  • 16 funds opened new Palvella Therapeutics positions in Q4 2018 and 21 closed out, a net change of -5 holders.
  • The largest Palvella Therapeutics buyer in Q4 2018 was BVF Inc, an estimated $7.2M added.
  • The largest Palvella Therapeutics seller in Q4 2018 was OrbiMed, an estimated $13.8M sold.

Based on aggregated 13F filings for Q4 2018.